AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
LOS ANGELES, March 24, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Egalet Corporation (“Egalet” or the “Company”) (Nasdaq:EGLT). Investors who purchased or otherwise acquired Egalet shares between December 15, 2015 and January 9, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The investigation is centered on whether Egalet and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On January 9, 2017, Egalet issued a statement regarding approval for its product Arymo ER. The same day, the U.S. Federal Drug Administration stated that another product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Due to MorphaBond’s exclusivity within this market, “no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.”
When this information was revealed to the investing public, the value of Egalet declined, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
